BeiGene

elsewhere's corpus does not actually cover BeiGene — no material here describes its founding, business, or financing. The retrieval surfaced instead 百曜科技 (Baiyao Technology), an AI virtual-cell (AIVC) platform company that appears repeatedly in the corpus and is likely what this query matched: built by a team drawing on the Chinese Academy of Sciences' Institute of Zoology and the Beijing Institute for Stem Cell and Regenerative Medicine, it began developing single-cell foundation models in 2023, and per 峰瑞资本's funding newsletters it raised a tens-of-millions RMB angel round led by FreeS Capital in late 2025 , followed by another tens-of-millions round in mid-2026 led by China Reform's venture fund with participation from 道彤资本 and 云启资本, bringing its AI-ready single-cell data base past 400 million cells . If you meant BeiGene (百济神州), the oncology company, elsewhere has no coverage of it to date.